» Articles » PMID: 34521143

Ventricular Assist Device Driveline Infections: A Systematic Review

Overview
Date 2021 Sep 14
PMID 34521143
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Infection is the most common complication in patients undergoing ventricular assist device (VAD) implantation. Driveline exit site (DLES) infection is the most frequent VAD infection and is a significant cause of adverse events in VAD patients, contributing to morbidity, even mortality, and repetitive hospital readmissions. There are many risk factors for driveline infection (DLI) including younger age, smaller constitution of patients, obesity, exposed velour at the DLES, longer duration of device support, lower cardiac index, higher heart failure score, DLES trauma, and comorbidities such as diabetes mellitus, chronic kidney disease, and depression. The incidence of DLI depends also on the device type. Numerous measures to prevent DLI currently exist. Some of them are proven, whereas the others remain controversial. Current recommendations on DLES care and DLI management are predominantly based on expert consensus and clinical experience of the certain centers. However, careful and uniform DLES care including obligatory driveline immobilization, previously prepared sterile dressing change kits, and continuous patient education are probably crucial for prevention of DLI. Diagnosis and treatment of DLI are often challenging because of certain immunological alterations in VAD patients and microbial biofilm formation on the driveline surface areas. Although there are many conservative and surgical methods described in the DLI treatment, the only possible permanent solution for DLI resolution in VAD patients is heart transplantation. This systematic review brings a comprehensive synthesis of recent data on the prevention, diagnostic workup, and conservative and surgical management of DLI in VAD patients.

Citing Articles

Incidence, risk factors and clinical outcome of multidrug-resistant organisms after heart transplantation.

Hatzianastasiou S, Vlachos P, Stravopodis G, Elaiopoulos D, Koukousli A, Papaparaskevas J World J Transplant. 2024; 14(2):93567.

PMID: 38947964 PMC: 11212582. DOI: 10.5500/wjt.v14.i2.93567.


Decreasing driveline infections in patients supported on ventricular assist devices: a care pathway approach.

Seretny J, Pidborochynski T, Buchholz H, Freed D, MacArthur R, Dubyk N BMJ Open Qual. 2022; 11(2).

PMID: 35649636 PMC: 9161071. DOI: 10.1136/bmjoq-2022-001815.


Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection.

Rojas S, Junghans S, Fox H, Lazouski K, Schramm R, Morshuis M Antibiotics (Basel). 2022; 11(5).

PMID: 35625246 PMC: 9137613. DOI: 10.3390/antibiotics11050602.


The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support.

Berardi C, Bravo C, Li S, Khorsandi M, Keenan J, Auld J J Clin Med. 2022; 11(7).

PMID: 35407630 PMC: 9000165. DOI: 10.3390/jcm11072022.